1 results match your criteria: "Fuji Toranomon Orthopaedics Hospital[Affiliation]"
Intravenous abatacept in Japanese patients with polyarticular-course juvenile idiopathic arthritis: results from a phase III open-label study.
Pediatr Rheumatol Online J
April 2019
Fuji Toranomon Orthopaedics Hospital, 1067-1 Kawashimata, Gotenba-shi, Shizuoka, 412-0045, Japan.
Article Synopsis
- A study was conducted to assess the effectiveness and safety of intravenous abatacept in Japanese children aged 4-17 with active polyarticular-course juvenile idiopathic arthritis (pJIA) who had previously received inadequate treatment.
- In a phase III trial involving 20 patients, the primary outcome showed a 90% response rate (JIA-ACR30) after 16 weeks of treatment, with significant improvements in other response rates over time.
- By Week 52, high levels of efficacy were maintained, with notable improvements in disease activity and function as measured by various clinical endpoints.